AACI partners with Medlive, a leader in expert-guided digital medical education, to expand access to high-quality educational resources for our members. Through this collaboration, AACI and Medlive develop and deliver a range of CME-accredited and non-CME educational offerings designed to provide timely, evidence-based insights on emerging therapies, evolving models of care, and key issues impacting cancer centers and care teams. These initiatives feature expert perspectives and practical insights to support continued learning, inform clinical practice, and advance cancer care.
Redefining the Relapsed Squamous NSCLC Treatment Paradigm: A Focus on an Emerging Chemo-Free Anti-CTLA Mechanism and Evidence
Live program launched November 11, 2026. Available on demand through June 11, 2027.
Target Audience: Community oncologists and regional oncology stakeholders
Program Overview: Patients with squamous non-small cell lung cancer (sqNSCLC) who progress after first-line anti-PD-(L)1 therapy still have few options beyond single-agent cytotoxic chemotherapy, and no approved anti-CTLA-4 antibody has shown meaningful single-agent activity in NSCLC. This program, designed for community oncologists and regional oncology stakeholders, examines that gap and an investigational approach being studied to address it. It opens with the unmet clinical needs in second-line and later sqNSCLC, including the role of regulatory T cells (Tregs) in resistance to PD-(L)1 blockade and the limits of first-generation anti-CTLA-4 antibodies.
Faculty then explain the mechanistic rationale for an investigational pH-sensitive anti-CTLA-4 antibody engineered for tumor-selective Treg depletion. The final segment reviews available efficacy and safety data from recent clinical trials vs chemotherapy and considers what efficacy monitoring and immune-related adverse event (irAE) management could look like in community settings.
Learn More
Optimizing Adjuvant Therapy in HR+/HER2- Early Breast Cancer: Aligning Risk, Evidence, and Real-world Insights from Patients and Clinicians
Live program launched October 19, 2026. Available on demand through June 11, 2027. Program expires October 19, 2027.
Continuing Medical Education (CME): 1.25 CME credits. Requests for credit must be made no later than October 19, 2027.
Target Audience: Breast cancer specialists, oncologists, advanced practice providers (NP/PA), nurses, pharmacists, gynecologists, surgeons
Program Overview: Despite advances in surgical and systemic therapy, approximately 20-30 percent of patients with hormone receptor (HR)-positive/HER2-negative early breast cancer will relapse within 10 years, with the majority classified as high risk via tumor-specific characteristics and genomic profiling. Through four concise, case-based modules, this activity will equip the multidisciplinary oncology team with practical strategies to individualize risk stratification, make evidence-based treatment selections, and provide long-term management for patients at ongoing risk for recurrence.
Two breast oncologists and an advanced practice provider will review pivotal trial data, explore the evolving role of ctDNA and liquid biopsy in detecting minimal residual disease, and address real-world barriers to treatment adherence and persistence. Patient video vignettes, patient/caregiver survey findings, and HCP practice-pattern insights will ground clinical discussions in authentic patient and provider experiences, ensuring learners leave with actionable strategies they can apply immediately to their own practices.
Learn More